A new painkiller that is said to be free of addiction risks may be transformative for treatment of acute pain, according to ...
The FDA has approved Journavx, a new non-opioid painkiller designed to treat moderate to severe acute pain. Unlike opioids, ...
If the attention generated by BioSpace’s coverage of this landmark approval is any indication, Americans are hungry for ...
The Food and Drug Administration on Thursday approved Journavx, a non-opioid painkiller that is the first novel pain drug to win government authorization in more than 20 years. Vertex ...
Journave, the first non-addictive opioid-like pain medication, was developed based on Yale research from the ’90s.
SALT LAKE CITY, UTAH / ACCESS Newswire / February 6, 2025 /CenExel, a leading network of clinical research sites, proudly ...
The FDA has approved a new non-opioid prescription medication, Journavx for adults with moderate to severe acute pain.
Introducing Journavx: the FDA-approved non-opioid, non-addictive drug for acute pain. A major breakthrough in pain medication ...
The Food and Drug Administration (FDA) has approved Journavxâ„¢ (suzetrigine) for the treatment of moderate to severe acute pain in adults.
That’s the opinion of top Vertex Pharmaceuticals executives and several market analysts about the Boston-based company’s painkiller Journavx, which the Food and Drug Administration approved on ...
The new drug will carry a list price of $15.50 per pill, making it many times more expensive than comparable opioids.
Vertex's Journavx got FDA approval for acute pain but faces adoption challenges: variable efficacy vs opioids, generic competition, and entrenched prescriber habits limit near-term potential.